Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Long-Term Investments (2019 - 2023)

ProQR Therapeutics' Long-Term Investments history spans 4 years, with the latest figure at $676222.0 for Q2 2023.

  • On a quarterly basis, Long-Term Investments rose 2.05% to $676222.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $676222.0, a 2.05% increase, with the full-year FY2022 number at $633573.6, up 6592.32% from a year prior.
  • Long-Term Investments hit $676222.0 in Q2 2023 for ProQR Therapeutics, up from $666545.3 in the prior quarter.
  • Over the last five years, Long-Term Investments for PRQR hit a ceiling of $696971.7 in Q1 2022 and a floor of $749.07 in Q1 2021.
  • Historically, Long-Term Investments has averaged $407074.6 across 4 years, with a median of $626138.4 in 2022.
  • Biggest five-year swings in Long-Term Investments: tumbled 92.83% in 2021 and later skyrocketed 92944.61% in 2022.
  • Tracing PRQR's Long-Term Investments over 4 years: stood at $127575.0 in 2020, then tumbled by 92.83% to $9151.8 in 2021, then soared by 6822.96% to $633573.6 in 2022, then grew by 6.73% to $676222.0 in 2023.
  • Business Quant data shows Long-Term Investments for PRQR at $676222.0 in Q2 2023, $666545.3 in Q1 2023, and $633573.6 in Q4 2022.